May 11, 2022 -- Advancements in the field of cell and gene therapies (CGTs) have made them a therapeutic reality, according to Bambi Grilley, director of clinical research and early product development at Baylor College of Medicine, and co-chair of the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting.
Grilley, a pharmacist by training, spoke with ScienceBoard.net at ISCT22 about the evolution of the CGT industry which is driving clinical translation of CGTs that are benefitting patients.
"Now that there's approved CGT products on the market, that's a whole other world," said Grilley, who is also chair of ISCT's North American Legal and Regulatory Affairs Committee. "My first ISCT meeting was Dublin, which I think was 22 years ago, and at that meeting, obviously, we were all talking science ... and now, we're talking about successful launches and trying to standardize the way products are released so that when you have [chimeric antigen receptor] CAR T cells there's not different rules for different products -- and all the sites that are using these products are trying to figure that all out."
Watch the video below to learn more.
Copyright © 2022 scienceboard.net